Matthewj Meyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Matthewj meyer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Matthewj Meyer Today - Breaking & Trending Today
/PRNewswire/ AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced. ....
Share this article Share this article HOUSTON, May 25, 2021 /PRNewswire/ AuraVax Therapeutics, Inc. (Auravax), a biotech company developing novel intranasal therapeutics and vaccines to help patients defeat debilitating respiratory diseases, including COVID-19, today announced the formation of its inaugural Scientific Advisory Board (SAB), consisting of leading experts in the fields of biology, vaccines and intranasal drug delivery. The SAB will guide and advise the company in its ongoing development of proprietary therapeutics and vaccines for respiratory diseases. The SAB is chaired by George M. Church, Ph.D. and includes Stephen Albert Johnston from Calviri, Inc and Mei X. Wu, Ph.D. from Massachusetts General Hospital/Harvard Medical School. ....
AuraVax Therapeutics Enters into Exclusive License Agreement with the University of Houston for Intranasal Vaccine and Therapeutics Technology Platform Transaction supports development of AuraVax s lead COVID-19 intranasal program, plus other vaccines and therapeutics targeting respiratory diseases News provided by Share this article Share this article HOUSTON, Feb. 3, 2021 /PRNewswire/ AuraVax Therapeutics Inc. (www.auravax.com), a pioneering biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases including COVID-19, today announced it has entered into an exclusive license agreement with the University of Houston (UH) with respect to the intellectual property covering a novel intranasal vaccine and STING agonist technologies. This agreement converts the optioned intellectual property between UH and AuraVax announced on October 12, 2020. ....
AuraVax Therapeutics Enters into Exclusive License Agreement with Massachusetts General Hospital for Intranasal Vaccine and Therapeutics Platform Transaction bolsters development of AuraVax s lead COVID-19 intranasal vaccine and strengthens platform for therapeutic development targeting a range of viral infections News provided by Share this article Share this article HOUSTON, Jan. 13, 2021 /PRNewswire/ AuraVax Therapeutics Inc. (www.auravax.com), a biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases, including COVID-19, today announced it has entered into an exclusive license agreement with Massachusetts General Hospital (MGH) covering certain intellectual property and technology rights regarding compositions and discoveries of liposomal STING agonists by Mei X. Wu, PhD, of the Wellman Center for Photomedicine at MGH. Research related to this technology was published in ....